Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Use of a Sensitive Chemiluminescence-Based Assay to Evaluate the Metabolic Suppression Activity of Linezolid on Methicillin-Resistant Staphylococcus aureus Showing Reduced Susceptibility to Vancomycin

  • Komatsu, Mitsutakal (Department of Pediatrics, Juntendo University, Infection Control Sciences, Juntendo University) ;
  • Tajima, Yutaka (Infection Control Sciences, Juntendo University) ;
  • Ito, Teruyo (Infection Control Sciences, Juntendo University, Department of Bacteriology, Juntendo University) ;
  • Yamashiro, Yuichiro (Department of Pediatrics, Juntendo University) ;
  • Hiramatsu, Keiichi (Infection Control Sciences, Juntendo University, Department of Bacteriology, Juntendo University)
  • Published : 2009.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Recently, strains of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin (VCM) have been clinically isolated. The antibacterial activity of a new drug, linezolid (LZD), in such a strain was evaluated by measuring bacterial metabolic activity. A total of 73 MRSA strains having various susceptibilities to VCM were subjected to a novel and highly sensitive chemiluminescence-based assay. LZD MIC in the tested strains, measured by the microbroth dilution method, was within the range 1-4 mg/l (mostly ${\leq}2$mg/l), except for one LZD-resistant strain (NRS127; MIC=7 mg/l), and showed no correlation with VCM resistance. The chemiluminescence assay demonstrated that bacterial metabolic activity was strongly suppressed with increasing LZD concentration. The chemiluminescence intensity curve had a low baseline activity without tailing in most strains. The present results suggest that LZD has strong antibacterial activity against MRSA strains, and would be effective for treatment of infections that are poorly responsive to VCM. The chemiluminescence assay facilitated sensitive and discriminative susceptibility testing within a relatively short time.

Keywords

References

  1. Clinical and Laboratory Standards Institute. 2005. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA
  2. Clinical and Laboratory Standards Institute. 2006. Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA
  3. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microb. 41: 5-14 https://doi.org/10.1128/JCM.41.1.5-14.2003
  4. Diekema, D. J. and R. N. Jones. 2001. Oxazolodinone antibiotics. Lancet 258: 1975-1982
  5. Dumitrescu, O., S. Boisset, C. Badiou, M. Bes, Y. Benito, M. E. Reverdy, F. Vandenesch, J. Etienne, and G. Lina. 2007. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob. Agents Chemother. 51: 1515-1519 https://doi.org/10.1128/AAC.01201-06
  6. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, F. C. Tenover, and the Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36: 429-439 https://doi.org/10.1086/346207
  7. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40: 135-136 https://doi.org/10.1093/jac/40.1.135
  8. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Res. Updates 1: 135-150 https://doi.org/10.1016/S1368-7646(98)80029-0
  9. Komatsu, M., Y. Tajima, T. Ito, Y. Yamashiro, and K. Hiramatsu. 2008. Time-suppression test using a colorimetric probe (alamarBlue) that measures bacterial metabolic activity. Biomed. Res. 29: 171-173 https://doi.org/10.2220/biomedres.29.171
  10. Manome, I., M. Ikedo, Y. Saito, K. K. Ishii, and M. Kaku. 2003. Evaluation of a novel automated chemiluminescent assay system for antimicrobial susceptibility testing. J. Clin. Microbiol. 41: 279-284 https://doi.org/10.1128/JCM.41.1.279-284.2003
  11. Moise, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2002. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50: 1017-1026 https://doi.org/10.1093/jac/dkf215
  12. Nagasawa, Z., I. Manome, and A. Nagayama. 2004. A rapid antimicrobial susceptibility test based on chemiluminescence assay and its application to screening of genotypes in vancomycinresistant enterococci. J. Infect. Chemother. 10: 220-226 https://doi.org/10.1007/s10156-004-0329-Z
  13. National Committee for Clinical Laboratory Standards. 2003. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 6th Ed. Approved Standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA
  14. Oliveira, G. A., A. M. Dell'Aquila, R. L. Masiero, C. E. Levy, M. S. Gomes, L. Cui, K. Hiramatsu, and E. M. Mamizuka. 2001. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control Hosp. Epidemiol. 22: 443-448 https://doi.org/10.1086/501932
  15. Romero-Steiner, S., W. Spear, N. Brown, P. Holder, T. Hennessy, P. Gomez De Leon, and G. M. Carlone. 2004. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin. Diagn. Lab. Immunol. 11: 89-93 https://doi.org/10.1128/CDLI.11.1.89-93.2004
  16. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340: 493-501 https://doi.org/10.1056/NEJM199902183400701
  17. Stevens, D. L., D. Herr, H. Lampiris, J. L. Hunt, D. H. Batts, and B. Hafkin. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 34: 1481-1490 https://doi.org/10.1086/340353
  18. Stevens, D. L., B. Dotter, and K. Madaras-Kelly. 2004. A review of linezolid: The first oxazolidinone antibiotic. Expert Rev. Anti Infect. Ther. 2: 51-59 https://doi.org/10.1586/14787210.2.1.51
  19. Tajima, Y., M. Komatsu, T. Ito, and K. Hiramatsu. 2007. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test. J. Microbiol. Methods 70: 434-441 https://doi.org/10.1016/j.mimet.2007.05.020
  20. Yamashoji, S., I. Manome, and M. Ikedo. 2001. Menadionecatalyzed $O_2$ - production by Escherichia coli cells: Application of rapid chemiluminescent assay to antimicrobial susceptibility testing. Microbiol. Immunol. 45: 333-340 https://doi.org/10.1111/j.1348-0421.2001.tb02628.x
  21. Walsh, T. R. and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56: 657-675 https://doi.org/10.1146/annurev.micro.56.012302.160806
  22. Zurenko, G. E., J. K. Gibson, D. L. Shinabarger, P. A. Aristoff, C. W. Ford, and W. G. Tarpley. 2001. Oxazolidinones: A new class of antibacterials. Curr. Opin. Pharmacol. 1: 470-476 https://doi.org/10.1016/S1471-4892(01)00082-0